Determined to accelerate reimbursement for Canadian patients, Christopher Lenhu currently oversees market access and pricing strategies across the entire BeiGene portfolio. Since joining BeiGene last year, he’s developed a framework for value-based contracting and innovative pricing models while collaborating across the organization to integrate market access planning into sales, marketing and medical strategies.

In his previous role at Seagen Canada, Christopher achieved national reimbursement for the oncology portfolio, enabling the company to grow from a single-product biotech firm to a multi-product firm acquired by Pfizer in 2023. Christopher has co-authored two real-world evidence studies in breast cancer and served as a mentor for pharmacy students at the University of Toronto.